Early Experience With the First Commercially Available Off-the-Shelf Multibranched Endograft (t-Branch) in the Treatment of Thoracoabdominal Aortic Aneurysms

• DOI: 10.1583/13-4428r.1
• Publication Date: 2013-12-10T15:50:22Z
• Authors: Michel J. Bosiers; Theodosios Bisdas; Konstantinos P. D...; Giovanni Torsello; Martin Austermann
• Keywords: Paraplegia

To assess the feasibility and safety of first commercially available off-the-shelf multibranched endograft for total endovascular repair thoracoabdominal aortic aneurysms (TAAA).Between November 2012 May 2013, 15 patients (10 men; mean age 70 years) with TAAA underwent implantation Zenith t-Branch device, which received European marketing approval in late 2012. Three presented symptomatic TAAAs, 2 had a chronic Stanford type B dissection false lumen expansion. In retrospective review prospectively collected data, primary endpoint was 30-day mortality from any cause; outcome measure technical success. Secondary endpoints were postoperative complications, including renal failure requiring dialysis, organ ischemia, spinal cord ischemia. Radiological outcomes, such as endoleak, further aneurysm expansion, branch occlusion, also assessed.Technical success 100%, all target vessels connected patent. There no function deterioration or Paraplegia observed one patient despite cerebrospinal fluid drainage monitoring. Four suffered transient paraparesis, completely resolved before discharge. in-hospital mortality. After follow-up 5 months, has died, there been occlusion I/III endoleaks.Use device treatment TAAAs is feasible safe, encouraging early clinical radiological outcomes. Long-term results are necessary to evaluate applicability performance this urgent setting.